共 50 条
Hypoglycemia in cystic fibrosis during an extended oral glucose tolerance test
被引:8
|作者:
Armaghanian, Natasha
[1
,2
,3
]
Hetherington, Julie
[4
]
Parameswaran, Venkat
[5
,6
]
Chua, Elizabeth L.
[7
,8
]
Markovic, Tania P.
[9
,10
]
Brand-Miller, Jennie
[11
,12
]
Steinbeck, Kate
[1
,2
]
机构:
[1] Childrens Hosp Westmead, Acad Dept Adolescent Med, Sydney, NSW 2145, Australia
[2] Univ Sydney, Discipline Child & Adolescent Hlth, Sydney, NSW, Australia
[3] Royal Prince Alfred Hosp, Dept Resp Med, Sydney, NSW, Australia
[4] Royal Prince Alfred Hosp, Endocrinol & Metab Ctr, Sydney, NSW, Australia
[5] Royal Hobart Hosp, Dept Diagnost Endocrinol, Hobart, Tas, Australia
[6] Univ Tasmania, Sch Med, Hobart, Tas, Australia
[7] Royal Prince Alfred Hosp, Dept Endocrinol, Sydney, NSW, Australia
[8] Univ Sydney, Fac Med & Hlth, Cent Clin Sch, Sydney, NSW, Australia
[9] Univ Sydney, Boden Collaborat Obes Nutr Exercise & Eating Diso, Sydney, NSW, Australia
[10] Royal Prince Alfred Hosp, Dept Endocrinol Metab & Obes Serv, Sydney, NSW, Australia
[11] Univ Sydney, Sch Life & Environm Sci, Sydney, NSW, Australia
[12] Univ Sydney, Charles Perkins Ctr, Sydney, NSW, Australia
关键词:
abnormal glucose metabolism;
cystic fibrosis;
hypoglycemia;
oral glucose tolerance test;
ALPHA-CELL;
GLP-1;
GUT;
ABNORMALITIES;
INCRETINS;
PANCREAS;
CHILDREN;
ADULTS;
D O I:
10.1002/ppul.25081
中图分类号:
R72 [儿科学];
学科分类号:
100202 ;
摘要:
Background: Hypoglycemia in cystic fibrosis (CF), in the absence of glucose-lowering therapies, has long been identified as an important issue in the management of CF. There is currently still no unifying hypothesis for its etiology. Aim: The aims of this study were to perform a 3-h oral glucose tolerance test (OGTT) in participants with CF and (1) document glucose, insulin, glucagon, glucagon-like-peptide-1 (GLP-1), and glucose-dependent insulinotropic peptide (GIP) release patterns within varying glucose tolerance groups during the OGTT; (2) determine the prevalence of hypoglycemic during the OGTT; and (3) define any association between hypoglycemia and patterns of insulin, glucagon, GLP-1, and GIP release. Methods: Eligible participants attending an adult CF clinic completed a 3-h OGTT. Hypoglycemia on OGTT was defined as mild (glucose 3.4-3.9 mmol/L), moderate (glucose 3.1-3.3 mmol/L), and severe (glucose <= 3 mmol/L). Hormones were measured at fasting, 30, 60, 120, and 180 min. Results: Twenty-four participants completed the study, of which 7 had normal glucose tolerance, 12 had abnormal glucose tolerance, and 5 had cystic fibrosis related diabetes (CFRD). All participants had a delayed insulin response compared with normative data. All glucose tolerance groups showed appropriate and similar suppression of fasting glucagon. Four participants (17%) had mild hypoglycemic, three (13%) had moderate hypoglycemic, and eight (33%) had severe hypoglycemic. No participant with CFRD demonstrated hypoglycemic. Of the 19 participants without CFRD, 15 (79%) experienced hypoglycemic. Participants with hypoglycemic had greater peak glucose and insulin responses than those that did not have hypoglycemic, and this approached significance (p = .0625 for glucose and p = .0862 for insulin). No significant mean differences between GLP-1 and GIP release were found. There was no relationship between hypoglycemic and modulator therapy. Conclusion: Postprandial hypoglycemic was unmasked by the extension of an OGTT to 3 h. Delayed and abnormal insulin release, and ineffective counter-regulatory action of glucagon may have a role in its etiology.
引用
收藏
页码:3391 / 3399
页数:9
相关论文